DOCSLIB.ORG

Tough Tech Is Everywhere

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tough Tech Is Everywhere Tough Tech is ... > Launching a satellite network to connect existing satellites to Earth 24/7. > A new process to produce steel more efficiently, at a lower cost, and with zero greenhouse gas emissions. > Developing gas sensing technologies that transform the gases around us into useful, quantifiable knowledge. > A natural, sustainable, and edible protective food coating that significantly increases shelf life and reduces food waste. > Transforming power electronics with a new generation of GaN-powered chips. > Pioneering the next pillar of the regenerative medicine industry through precision cell production. > Creating safe, unlimited, carbon-free fusion power for the grid in 10-15 years. > Enabling rapid, accurate diagnosis of infectious disease at the point of care. > Engineering a bidirectional power plant to make renewable energy available 24/7. > Producing ultra-efficient chip-scale optical circuits to de-bottleneck data centers, telecommunication networks, and secure quantum communications. CONTENTS a. b. | 04 | | 06 | Industry Tough Tech Summit 2019 c. d. e. A home for Tough Tech founders. | 26 | | 42 | | 54 | The Engine, built by MIT, is a venture firm that invests in early-stage The Dream Nature Cleaning companies solving the world’s biggest problems through the convergence of of Anything Amplified Up Steel Anywhere breakthrough science, engineering, and leadership. Our mission is to accelerate the path to market for Tough Tech companies through access to a unique combination of investment, infrastructure, and a vibrant ecosystem. Tough Tech Publication 04 f. November 2019 Editor: Nathaniel Brewster The Engine, Built by MIT Design: www.draft.cl | 68 | Print by Puritan Capital, NH & MA The Engine Portfolio Companies TOUGH TECH 04 TOUGH TECH 04 | | 6 7 | Industry | The way we make things is changing. Essential things like steel, cement, and chemicals. Everyday things like shoes and tools. Complex things like rockets and biological organisms. This change is thanks to a unique convergence of materials, technologies, and processes maturing in unison. These new technologies and processes are the things that help us make other things. not simply different from the status quo, They are the foundation upon which the they are, in almost all cases, more efficient, necessities of life are built and hold enormous less expensive, and far less polluting than commercial, environmental, and societal value. their traditional counterparts. This new industrial Tough Tech is developed, in many This edition of Tough Tech highlights cases, with the express purpose of tackling three facets of the Tough Tech industrial the planet’s biggest challenges like climate revolution: the race to eliminate greenhouse change and human health. gas emissions from steel, cement, and chemical production; the blossoming and Much of this new industrial revolution is dynamic additive manufacturing industry; hidden from the public eye — these are and how biology is harnessed to produce technologies and processes that make industrial products at scale. Tough Tech SummitSM Forging a Path for Tough Tech. TOUGH TECH 04 | TOUGH TECH 04 | Our second invite-only conference of “Solving the global-scale problems Tough Tech companies 8 founders, investors, academics, policy are tackling requires commitment and collaboration. 9 | | makers, and business leaders explored The only way we solve fundamental challenges in climate, the challenges of bringing Tough Tech to human health, infrastructure, and computing is together.” market, and investigated the business, technical, and financial strategies needed The Tough Tech Summit has one goal — unite a community to support founders as they build companies tackling some of the world’s hardest to accelerate the commercial success of problems. I saw 500 individual members of such a community — world-changing companies. entrepreneurs, academics, policy makers, business leaders, investors, and the founders themselves — work together over two days to push these companies, and their ideas, forward. All were there because they believe in the convergent power of people, technology, and science to change the world. It was as humbling as it | was inspiring. Build 10.21. Invest 10.22. As you browse this publication, I hope it inspires you to ask yourself how you can help founders’ ambition scale to the level where their companies thrive Day one, Build, featured a fireside chat other Tough Tech founders and investors. commercially. I challenge you to ask yourself how you can make the path with Vinod Khosla, founder keynotes, case Josh DeFonzo, Peter Hebert, and Bijan faster and easier for these entrepreneurs — if we all do that, imagine what we study workshops, and interactive panels. Salehizadeh, some of the lead investors, Attendees worked together to help solve advisors, and executives behind Auris can create! If we get it right — when we get it right — we can create a Tough some of the core challenges faced by Tough Health, had a frank and illuminating Tech ecosystem that needs no introduction. Tech companies. discussion about the company’s journey from startup to multi-billion-dollar During day two, Invest, founders pitched acquisition. The day also featured panel Katie Rae their businesses and connected with sessions and open networking time. CEO & Managing Partner Tough Tech Summit DAY 1: DAY 2: DAY 1 & 2: 192 101 207 500 UNIQUE ATTENDEES UNIQUE ATTENDEES UNIQUE ATTENDEES UNIQUE ATTENDEES Build 10.21. DAY 1 Invest 10.22. DAY 2 33% 27% 28% 40% ENTREPRENEURS INVESTORS ENTREPRENEURS INVESTORS TOUGH TECH 04 TOUGH TECH 04 MEMBERS OF THE TOUGH TOUGH TECH FOUNDERS TECH ECOSYSTEM AND ENTREPRENEURS MEMBERS OF THE TOUGH | | TOUGH TECH FOUNDERS 10 TECH ECOSYSTEM 39 11 MEMBERS OF AND ENTREPRENEURS | | GOVERNMENT 18 123 17 81 ATTENDEES MEMBERS OF GOVERNMENT 16 399 ATTENDEES STRATEGIC INVESTORS STRATEGIC CORPORATES INVESTORS 306 CORPORATES LEADERS 45 IN ACADEMIA 107 32 122 36 Platinum Partners Gold Partners Tough Tech SummitSM “To us at The Engine, the future will be filled with more empowered founders building technology, teams, and companies. And those companies will know where to look for support.” TOUGH TECH 04 “We have one goal today: to further develop a TOUGH TECH 04 community that supports these founders as they build companies tackling some of the world’s hardest problems.” | | 12 Katie Rae 13 | | CEO & Managing Partner, The Engine “The team you build is the company you build.” “Skeptics have never done the impossible. Keep that in mind. It’s religion for me. I’d rather try and fail than fail to try it.” “If you ask three experts and all three say, yeah, this is not doable, then you have to worry. If they all say it’s doable, then you have to worry that too many people will do it. So you have to exist in this other space where people doubt it can be done.” Vinod Khosla Founder & Partner, Khosla Ventures Build 10.21. Tough Tech Summit Case Studies SOLIDIA TECHNOLOGIES FORMLABS D-WAVE & LOCKHEED MARTIN Ann DeWitt | Moderator Milo Werner | Moderator Reed Sturtevant | Moderator General Partner, The Engine Partner, Ajax Strategies General Partner, The Engine Jim Matheson | Moderator Max Lobovsky Vern Brownell Senior Lecturer in Business Administration, Co-Founder & CEO, Formlabs CEO, D-Wave Harvard Business School Dávid Lakatos Ned Allen Nick DeCristofaro Chief Product Officer, Formlabs Chief Scientist, Lockheed Martin CTO, Solidia Technologies TOUGH TECH 04 TOUGH TECH 04 In 2011, Formlabs was in its early days, working When D-Wave built the first working quantum computer, As Solidia Technologies, a sustainable cement and on a prototype for a low-cost, prosumer-oriented it had no customers. How did it sell this computer, a concrete technology company, began its path toward stereolithography 3D printer. With the long-term vision technology that no one had ever bought before? And why commercialization, it was faced with a core business model of internalizing key parts of their supply chain, they were did Lockheed Martin, D-Wave’s first customer, take the decision — become a cement and concrete company and looking for an immediate partnership that would help them leap and make the purchase when there was no precedent | | seek to disrupt the industry’s major players, or become hit the ground running. for doing so? 14 15 a technology provider and disrupt the industry’s carbon | | footprint without being disruptive to established business In just a few years, Formlabs has grown to be the largest For Lockheed Martin, who produces complex cyber- and manufacturing processes. part of their partner’s business, with the expectation of physical systems, the possibility of reducing the cost and overwhelming their production in the near future. With time of software verification and validation (V&V) was too Solidia decided to think big — to sell its technology to the desire to have more control over its supply chain at great to ignore. Lockheed spends tens of millions every year major manufacturers of cement and concrete, taking current and future scale, Formlabs is faced with a number on V&V — in fact, 60 percent of production cost is related advantage of the established global supply chain to scale of options: acquire their current partner, find a new, bigger to V&V of the system. It is, in the words of Ned Allen, the quickly and efficiently. With this business model, the partner, or build their own facility. company’s chief scientist, “a humongous problem.” company’s technology has the potential to eliminate at least 1.5 gigatons of CO2 per year. What we learned: Allen at Lockheed had to ensure that the money his “Maintaining control of supply is super important for us. In the company invested in D-Wave’s quantum computer would Nick DeCristofaro, CTO of Solidia, shared four reasons 3D printing world, your material is your special sauce. People not be lost, even if the initial goal of the program was why his company decided to pursue its current technology- are buying your printers for their performance.
Load more

Recommended publications
  • Annual Report
    Fiscal Year 2015 Annual Report To: Governor Charlie Baker Secretary of Administration and Finance Kristen Lepore Secretary of Housing & Economic Development Jay Ash Senate President Stan Rosenberg Speaker of the House Robert DeLeo State Comptroller Thomas G. Shack III Clerk of the Senate William Welch Clerk of the House of Representatives Steven James By forward: House and Senate Committees on Ways and Means and the Joint Committee on Economic Development and Emerging Technologies Date: September 30, 2015 Re: FY 2015 Annual Report of the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (MLSC) respectfully submits this Annual Report detailing the organization’s operations and accomplishments during Fiscal Year (FY) 2015. For the past seven years, the MLSC has led the state’s life sciences initiative – a $1 billion initiative designed to strengthen the state’s economy by accelerating the growth of our life sciences sectors in Massachusetts. The MLSC’s goal has been to make Massachusetts the strongest life sciences ecosystem in the world and the best place in the world for life sciences companies to do business. The MLSC collaborates with the private sector to accelerate the pace of innovation and economic development in all regions of Massachusetts. The MLSC’s strategy has been based on the belief that the best role for the state is to invest in Massachusetts’ innovation capacity – the ability to produce and commercialize a flow of innovative life sciences technologies over the long term. Since 2008, the MLSC has invested aggressively in five “enablers” that build innovation capacity: translational research, entrepreneurship, workforce development, infrastructure and collaboration.
    [Show full text]
  • View Annual Report
    GENOCEA BIOSCIENCES, INC. FORM 10-K (Annual Report) Filed 02/27/15 for the Period Ending 12/31/14 Address 100 ACORN PARK DRIVE CAMBRIDGE, MA 02140 Telephone 617-876-8191 CIK 0001457612 Symbol GNCA SIC Code 2836 - Biological Products, Except Diagnostic Substances Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36289 Genocea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 51 -0596811 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 100 Acorn Park Drive Cambridge, Massachusetts 02140 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (617) 876-8191 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which Title of each class registered Common Stock, $0.001 par value NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Annual Report
    HUMAN CAPITAL FISCAL YEAR 2019 ANNUAL REPORT INNOVATION CAPITAL GROWTH CAPITAL INTELLECTUAL CAPITAL The capital of scientific revolution. Fiscal Year 2019 Annual Report • Massachusetts Life Sciences Center • i BOARD OF DIRECTORS TABLE OF CONTENTS A LETTER FROM THE INTERIM PRESIDENT & CEO Michael J. Heffernan Co-Chair; Secretary, Executive Office for Administration & Finance A Letter from the President & CEO ...........................................................................................1 Mike Kennealy Co-Chair; Secretary, Executive Office Vision & Strategy: The Capital of Scientific Revolution ......................................................2 The Patients Are Waiting of Housing & Economic Development Fiscal Year 2019 Highlights and The Bottom Line ..............................................................3 Gary P. Kearney, MD Around the globe, billions of patients and their loved ones await advances in health President, Longwood Urological Associates Human Capital care that will produce the products, devices, and therapies to alleviate suffering, Marty Meehan Internship Challenge: Enhancing Career Exploration improve treatment, and save lives. Much of that attention falls on Massachusetts, as President, University of Massachusetts and Expanding the Talent Pipeline ............................................................................................4 the world looks to our ecosystem to deliver the breakthroughs that further unlock our Peter Parker understanding of human physiology, harness the power of data science,
    [Show full text]
  • Science-USA (Boston+), November 2012
    Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Science-USA (Boston+), November 2012 Table of Contents 1. Policy ........................................................................................................................................................................................ 1 2. Education .................................................................................................................................................................................. 2 3. Life Science .............................................................................................................................................................................. 3 4. Nano / Micro Technology / Material Science ............................................................................................................................. 4 5. Information & Communications Technology ............................................................................................................................. 6 6. Energy / Environment ............................................................................................................................................................... 6 7. Engineering / Robotics / Space ................................................................................................................................................. 8 8. Physics / Chemistry / Math ......................................................................................................................................................
    [Show full text]
  • LIVIO VALENTI CV 2011-Present VAXESS TECHNOLOGIES, INC
    LIVIO VALENTI CV Livio Valenti is the co-founder of Vaxess Technologies and Giorgio Ruffolo Research Fellow in the Sustainability Science Program at Harvard Kennedy School of Government and the Harvard Global Health Institute. He received a Master in Public Policy from Harvard’s Kennedy School of Government in 2013, where he was the recipient of the Empedocle Maffia Fellowship provided by the Italian Government to one outstanding individual to attend Harvard. While a student at Harvard, he co-founded Vaxess Technologies, an innovative life sciences company that aims to create vaccines that do not need refrigeration. Vaxess has raised $4.75m in venture capital, angel investors, and various public institutions, including the Massachusetts Life Science Center (MLSC). Harvard Business School (HBS) published a case on Vaxess in 2014. Livio was named by Forbes one of the 30 under 30 individuals likely to change the world for his commitment in improving global health and one of the 10 under 40 (PrimiDieci-Under40 2014) most distinguished individuals with Italian origins or Italian nationality currently in the USA by the Italian-American Chamber of Commerce and the Italian Ministry of Foreign Affairs. His academic research at Harvard focuses on the space at the intersection between Government and Business. Livio is researching the potential to sustainably commercialize innovative technologies to improve global health. He is contributing to collaborative work with the Initiative on Innovation and Access to Technologies for Sustainable Development led by William Clark. Professional experience Prior to studying at Harvard, Livio worked for the United Nations in several developing countries. His work included advising government clients and international financing institutions in the identification, appraisal and financing of large investment projects.
    [Show full text]
  • Genocea Biosciences, Inc. (Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Genocea Biosciences, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the (3) filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee o was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Genocea Biosciences, Inc.
    [Show full text]
  • RENT a BENCH Biotech Incubators Such As Labcentral Are Lowering Barriers to Entrepreneurship by Trisha Gura, in Cambridge, Massachusetts
    NEWS | FEATURES | ENTREPRENEURSHIP GOT A STARTUP? RENT A BENCH Biotech incubators such as LabCentral are lowering barriers to entrepreneurship By Trisha Gura, in Cambridge, Massachusetts ith its cookie-cutter windows and square-meter facility, now owned by the boxy brick exterior, the build- Massachusetts Institute of Technology ing here on Main Street could be (MIT) and leased to LabCentral, functions just another former 19th century as a life science “incubator” that helps bud- W warehouse or factory. It’s no sur- ding biotech firms combat the soaring costs prise to learn that passenger rail- of lab space and equipment in the red-hot road cars were once built in its spacious Boston-Cambridge region. Any scientist on June 11, 2015 interior. Yet the Cambridge landmark has with an idea and ambition can rent a bench a history not just of production, but also and an office, sharing space, services, and of innovation. In 1876, it housed the office high-cost tools with others pursuing their of Thomas Watson, assistant to Alexander own entrepreneurial dreams. “It is very ex- Graham Bell, when the pair made the first citing because we are there at the nascent two-way long-distance phone call, to Bos- moment of many really, really cool com- ton. In the 20th century, it was home to Po- panies,” says molecular biologist Johannes laroid and the lab of Edwin Land when he Fruehauf, a LabCentral founder. invented the instant camera. It’s also the nascent moment for facili- www.sciencemag.org Today, a nonprofit organization called ties like LabCentral.
    [Show full text]
  • Class of 2013 Employment Overview 76
    HARVARD KENNEDY SCHOOL 617-495-1161 [email protected] www.hks.harvard.edu/career CAREER ADVANCEMENT t t t EMPLOYMENT OVERVIEW Class of 2013 HARVARD KENNEDY SCHOOL t CLASS OF 2013 EMPLOYMENT OVERVIEW This overview reflects the diverse employment choices of Harvard Kennedy School (hks) class of The following report on the class of 2013 May graduates immediately post-graduation. 2013 is based on data collected from The Kennedy School degrees continue to show May through October 2013. The hks resilience in an uncertain economy, with our Office of Career Advancement (oca) employed a variety of data collection graduates settling around the globe and across techniques including an exit survey sectors and industries. We invite you to read taken at graduation, a follow-up survey about how our graduates have chosen to serve in September, and individual email inquiries. Overall response rate was 91 the public good through their professional work. percent; of those, 90 percent reported employment or plans to continue in an educational program as of October. OVERVIEW OF GRADUATING 2013 CLASS from 76 539 students countries 242 international MPA/ID MPA2 62 82 12 43 Concurrent/ Concurrent/ Joint Degree Joint Degree MC/MPA MPP 202 193 32 Concurrent/ Joint Degree 87 Concurrent/Joint Degree Students MBA: 69 / Law: 11 / MD: 5 / Divinity: 1 / Design: 1 HARVARD KENNEDY SCHOOL 617-495-1161 [email protected] www.hks.harvard.edu/career CAREER ADVANCEMENT t t t EMPLOYMENT OVERVIEW Class of 2013 HIGHLIGHTS GRADUATES t Eight graduates were selected as t Nonprofit/ngo employment is down IN 2013 finalists in the U.S.
    [Show full text]
  • Fiscal Year 2015 Annual Report
    Fiscal Year 2015 Annual Report To: Governor Charlie Baker Secretary of Administration and Finance Kristen Lepore Secretary of Housing & Economic Development Jay Ash Senate President Stan Rosenberg Speaker of the House Robert DeLeo State Comptroller Thomas G. Shack III Clerk of the Senate William Welch Clerk of the House of Representatives Steven James By forward: House and Senate Committees on Ways and Means and the Joint Committee on Economic Development and Emerging Technologies Date: September 30, 2015 Re: FY 2015 Annual Report of the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (MLSC) respectfully submits this Annual Report detailing the organization’s operations and accomplishments during Fiscal Year (FY) 2015. For the past seven years, the MLSC has led the state’s life sciences initiative – a $1 billion initiative designed to strengthen the state’s economy by accelerating the growth of our life sciences sectors in Massachusetts. The MLSC’s goal has been to make Massachusetts the strongest life sciences ecosystem in the world and the best place in the world for life sciences companies to do business. The MLSC collaborates with the private sector to accelerate the pace of innovation and economic development in all regions of Massachusetts. The MLSC’s strategy has been based on the belief that the best role for the state is to invest in Massachusetts’ innovation capacity – the ability to produce and commercialize a flow of innovative life sciences technologies over the long term. Since 2008, the MLSC has invested aggressively in five “enablers” that build innovation capacity: translational research, entrepreneurship, workforce development, infrastructure and collaboration.
    [Show full text]
  • What's Inside
    Newsletter A publication of the Controlled Release Society Volume 34 • Number 2 • 2017 What’s Inside Formulation and Delivery of Mono-N-Oxide Vinblastine Liposomal Formulation for Targeting Non-Small Cell Lung Cancer with Hypoxic Environments In Vitro and In Vivo Evaluation of Controlled Payload Release Using Acoustically Responsive Scaffolds CRS Annual Meeting DDTR Update Science. People. Products. Connect and collaborate with delivery science and technology leaders from academia and industry, under one roof at #CRSboston Join us in Boston, Massachusetts, U.S.A. from July 16–19 for the 2017 Controlled Release Society Annual Meeting & Exposition. Registration is now open! Visit controlledreleasesociety.org/CRSboston for details. 2 Newsletter Ryan Donnelly Vol. 34 • No. 2 • 2017 Editor > TABLE OF CONTENTS 4 From the Editor 5 2017 Controlled Release Society Annual Meeting & Exposition Steven Giannos 7 Scientifically Speaking Editor Formulation and Delivery of Mono-N-Oxide Vinblastine Liposomal Formulation for Targeting Non-Small Cell Lung Cancer with Hypoxic Environments 10 Scientifically Speaking In Vitro and In Vivo Evaluation of Controlled Payload Release Using Acoustically Responsive Scaffolds 13 DDTR Update Drug Delivery and Translational Research Update Medha Joshi Editor 14 People in the News 15 Companies in the News Cover image: Malignant effusion: Pleural fluid cytology of lung (pulmonary) papillary adenocarcinoma, a type of non small cell carcinoma. Pap stain. David Litman / Shutterstock.com Arlene McDowell Editor Bozena Michniak-Kohn Editor Rod Walker Editor 3 > FROM THE EDITOR Editors Ryan Donnelly Steven Giannos Steven Giannos Medha Joshi University of Texas Medical Branch Arlene McDowell Galveston, TX, U.S.A. Bozena Michniak-Kohn Rod Walker The CRS Newsletter is the official Please Come to Boston newsletter of the Controlled Release Society.
    [Show full text]
  • Resi Program Final High
    redefining eARLY sTAGE iNVESTMENTs RESI 3 Early Stage Life Science Investment Just Hit a Home Run! ONSITE GUIDE September 17, 2014 Fenway Park Boston, MA RESIConference.com #RESI3 LifeScienceNation.com EMC Level FENWAY PARK EMC CLUB 3 LEVEL 3 EMC2 SUITE L2 Exit FIELD VIEW Board Room Exit Exit Stairs/Escalators workshopS TO State st. Bar Area pavilion LEVEL PARTNERING Forum REGISTRATION sTATE sTREET PAVILION Level State Street. PAVILION lEVEL 4 FENWAY PARK pRESS ROOM mEDIA dINING TRACK 2 TRACK 1 Exit 13 1 2 12 1 FIELD VIEW 2 12 3 Exit Exit 11 11 3 4 10 10 4 5 5 6 6 7 7 8 9 9 8 15 25 16 25 16 26 32 17 30 17 26 27 28 29 30 31 18 24 27 28 29 18 Stairs/Escalators 24 19 23 23 22 22 21 21 20 20 19 13 14 14 15 Bar Area PANELS Exhibiting companies TO EMC LEVEL pRESENTING companies contents TABLE OF CONTENTS Welcome from Dennis Ford - - - - - - - 2 RESI Schedule - - - - - - 3 Investor Panels - - - - - - - 5 Early Stage Workshops - - - - - - 25 Partnering Forum - - - - - - - 26 RESI Innovation Challenge - - - - - - - 27 Exhibiting Companies - - - - - - 29 Sponsors - - - - - - - 30 Media Partners - - - - - - - 33 1 welcome to resi Life Science Nation would like to welcome you to the third Redening Early Stage Investments (RESI) conference. We're excited to see you here at our new landmark location, Fenway Park. I hope you are ready to get the most out of a day lled with content, meetings and opportunities for everyone who has a stake in the early-stage life science sector.
    [Show full text]
  • Vaxess' Long Road to Heat-Stable Vaccines
    Case Number 2081.0 Technological Innovation for Global Health: Vaxess’ Long Road to Heat-Stable Vaccines It was only April, but 2015 was shaping up to be a busy one for Livio Valenti. The Harvard Kennedy School graduate was named to Forbes’ prestigious “30 under 30” list of the brightest entrepreneurs in science and healthcare, just as Vaxess Technologies, the biotech start-up he co-founded in 2012, was starting to attract atten- tion. Indeed, the company was awarded a research grant from the U.S. National Science Foundation and the U.S. National Institute of Health to put toward the development of heat-stable vaccines—a major honor and accom- plishment, though the grants themselves were modest. Most vaccines had to be refrigerated (or frozen) to preserve their efficacy. However, keeping vaccines at the appropriate temperature from manufacturer to recipient posed significant costs and logistical challenges, especial- ly in many low- and middle-income countries where the majority of the world’s children lived. Valenti believed Vaxess’ technology could provide a potentially simpler, safer approach to heat-stabilizing vaccines from both a scientific and regulatory standpoint—formulating them to withstand a lack of refrigeration—compared to other preservation techniques. In the vaccine field however, the risks and costs of research and development, and lengthy regulatory approval processes were major challenges to advancing products to market. Furthermore, with the greatest need for heat-stable vaccines in developing countries, market incentives for companies to invest in heat-stabilization research and development (R&D) were weak. Still, the U.S. Food and Drug Administration (FDA) had approved silk fibroin—the key ingredient for Vaxess’ platform to heat-stabilize vaccines—for use in medical devices such as surgical sutures and implantable surgical mesh, giving the Vaxess team confidence that their inno- vation would eventually gain FDA approval.
    [Show full text]